Ju-Young Park

Title: Ju-Young Park: Innovator in Therapeutic Protein Development

Introduction

Ju-Young Park is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic proteins. With a total of 3 patents, his work focuses on innovative solutions for metabolic diseases.

Latest Patents

Ju-Young Park's latest patents include groundbreaking inventions such as long-acting FGF21 fusion proteins and dual function proteins. The first patent provides a fusion protein comprising an FGF21 mutant protein and an Fc region of an immunoglobulin. This fusion protein exhibits improved pharmacological efficacy, in vivo duration, and protein stability. It is designed to be used as a therapeutic agent for conditions such as diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. The second patent introduces a dual function protein that links a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin. This dual function protein also shows enhanced pharmacological efficacy and stability, making it a promising candidate for treating various metabolic and cardiovascular diseases.

Career Highlights

Throughout his career, Ju-Young Park has worked with notable companies such as Yuhan Corporation and Samsung Display Co., Ltd. His experience in these organizations has contributed to his expertise in the field of therapeutic protein development.

Collaborations

Ju-Young Park has collaborated with talented individuals, including Jun Hwan Kim and Seyoung Lim, who have contributed to his research and development efforts.

Conclusion

Ju-Young Park is a distinguished inventor whose work in therapeutic proteins has the potential to significantly impact the treatment of metabolic diseases. His innovative patents reflect his commitment to advancing medical science and improving patient outcomes.